TELO

Telomir Pharmaceuticals, Inc. (TELO) - 10-Q Summary

Business Context and Reporting Period

Telomir Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing novel small-molecule therapeutics for cancer, with a lead candidate, Telomir-Zn, targeting triple-negative breast cancer (TNBC). The company operates as a single segment and is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. This report covers the quarterly period ended June 30, 2026.

On April 22, 2026, the company consummated a merger with TELI Pharmaceuticals, Inc., a related party, consolidating global intellectual property rights for Telomir-Zn. The transaction involved the issuance of 34,389,710 shares of common stock and a $1.0 million cash contribution from a related party (Bayshore Trust).

Key Financial Metrics

Note: The significant increase in Net Loss Attributable to Common Stockholders includes a non-cash "deemed dividend" of $46,113,903 resulting from the related-party merger accounting.

Material Changes vs. Prior Period

• Operating Expenses: Total operating costs decreased significantly from $5.07 million in the three months ended June 30, 2025, to $1.76 million in the same period in 2026. This reduction was primarily driven by a $3.9 million decrease in stock-based compensation expenses.
• Research & Development (R&D): R&D expenses increased from $42,839 in Q2 2025 to $444,674 in Q2 2026, reflecting higher pre-clinical research and consultant costs associated with advancing the Telomir-Zn program.
• Capital Structure: Common shares outstanding more than doubled from 34.4 million (Dec 31, 2025) to 68.8 million (June 30, 2026) due to the issuance of shares in the TELI merger.
• Liquidity: Cash balances decreased from $7.29 million at year-end 2025 to $5.17 million at June 30, 2026, due to a net cash burn of $2.79 million from operating activities.

Outlook, Risks, and Contingencies

Liquidity and Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. With approximately $5.2 million in cash and a burn rate of roughly $2.8 million over the last six months, the company expects to fund operations only through the first quarter of 2027 without additional financing.

Funding Commitments: Bayshore Trust has committed to provide up to $4.0 million in additional funding contingent on milestones: $2.0 million upon FDA acceptance of the IND application and another $2.0 million upon initiation of a Phase 1/2 clinical study. No funding has been received under this commitment as of June 30, 2026.

Legal Proceedings: On June 5, 2026, the Estate of former CEO Christopher Columbus Chapman, Jr. filed a lawsuit claiming damages in excess of $3.5 million for the failure to timely transfer restricted stock. The company intends to vigorously defend the claim, and no liability has been accrued.

Risks: Key risks include the inability to secure additional funding, failure to obtain regulatory approval for Telomir-Zn, and the outcome of pending litigation.

Investor Verification Checklist

• Going Concern Status: Verify the timeline for the next capital raise given the "substantial doubt" disclosure and limited cash runway (Q1 2027).
• Merger Accounting: Confirm the impact of the $46.1 million deemed dividend on earnings per share and equity structure.
• Related Party Transactions: Review the terms of the Bayshore Trust funding commitment and the extent of related party control (Bayshore Trust and Erez Aminov hold significant ownership).
• Litigation Exposure: Monitor the status of the $3.5 million lawsuit filed by the former CEO's estate.
• Stock-Based Compensation: Note the recent modification of stock options (May 2026) which triggered $588,000 in incremental expense, and assess future dilution risks.